Congenital
MemoPartTM occluders obtained the CE certificate in 2012. In the same year, MemoPartTM entered overseas markets. About 140,000 patients with structural heart disease worldwide have been treated with MemoPartTM occluder.
MemoPartTM occluders obtained the CE certificate in 2012. In the same year, MemoPartTM entered overseas markets. About 140,000 patients with structural heart disease worldwide have been treated with MemoPartTM occluder.
